Skip to main content
. 2017 Nov 4;7:91–93. doi: 10.1016/j.ctro.2017.11.002

Table 1.

Patient, tumor, and radiation characteristics.

No. (%), n = 166 Median (range)
Age, years 75 (23–95)
Sex
 Male 68 (41.0)
 Female 98 (59.0)



Primary tumor site
 Lung 154 (92.8)
 Gastrointestinal 8 (4.8)
 Thyroid 1 (0.6)
 Genitourinary 3 (1.8)



Histology
 Adenocarcinoma 152 (91.6)
 Squamous cell carcinoma 9 (5.4)
 Other 5 (3.0)
Tumor size, cm 2.0 (0.6–5.6)
 <2.0 cm 82 (49.7)
 ≥2.0 cm or <3.0 cm 42 (25.5)
 ≥3.0 cm or <4.0 cm 25 (15.2)
 ≥4.0 cm 16 (9.7)



AKT1 mutation status
 Present 1 (0.6)
 Absent 165 (99.4)



EGFR mutation status
 Present 35 (21.1)
 Absent 131 (78.9)



PIK3CA mutation status
 Present 6 (3.6)
 Absent 160 (96.4)
SBRT total dose, Gy 48 (30–70)
SBRT total fractions 4 (3–10)
BED,*Gy 106 (48–180)
 <100 Gy 41 (24.7)
 ≥100 Gy 125 (75.3)



Local failure status
 No 150 (90.4)
 Yes 16 (9.6)



Survival status
 Alive 114 (68.7)
 Dead 52 (31.3)

Abbreviations: BED = biologically effective dose; Gy = Gray; SBRT = stereotactic body radiation therapy.

*

BED based on alpha/beta of 10.